Abstract
Multiple Myeloma (MM) is part of a spectrum of plasma cell disorders that may result in end organ damage. MM is subclassified into high and standard risk based on cytogenetic and laboratory markers. The treatment of newly diagnosed multiple myeloma is constantly changing with the advent of novel therapies. Recent advances in therapies have resulted in longer time to remission and overall survival. the introduction of targeted therapy with monoclonal antibodies such as Daratumumab has improved stringent complete response to 39%.
Original language | English (US) |
---|---|
Pages (from-to) | 3694-3711 |
Number of pages | 18 |
Journal | Advances in Therapy |
Volume | 38 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2021 |
Keywords
- Multiple myeloma
- Therapeutic approaches
ASJC Scopus subject areas
- Pharmacology (medical)